Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
Conclusion: Alirocumab is not cost-effective in general MI population based on current discounted price. High long-term costs of alirocumab may be offset by health benefit in patients with polyvascular disease (3 beds).
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | China Health | Cholesterol | Drugs & Pharmacology | Heart | Heart Attack | Ischemic Stroke | Statin Therapy | Stroke | Study